Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up

• Κύριοι συγγραφείς: Antonio Lacquaniti (Συγγραφέας), Patrizio Pasqualetti (Συγγραφέας), Teresa Casuscelli di Tocco (Συγγραφέας), Susanna Campo (Συγγραφέας), Stefania Rovito (Συγγραφέας), Maurizio Bucca (Συγγραφέας), Antonino Ragusa (Συγγραφέας), Paolo Monardo (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: The Korean Society of Nephrology, 2020-09-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Background : : Ferric carboxymaltose (FCM) is a parenteral, dextran-free iron formulation designed to overcome the limitations of existing iron preparations. The main aim of this study was to retrospectively examine results obtained from a long period of FCM therapy in hemodialysis patients who have...